Table 3.
Criteria of development based on GI illness health risk values based on microbial targets measured at study site during the beaches epidemiologic study [34].
| Sampling day | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Microbe measure | Enterococci by MF (CFU/100 mL) |
<2 | 15* | 4* | 15 | 13 | 99 | 109* | <2 | 3 | 29* | 50 | 13 | <2* | 14 | <2 |
| F− coliphage (PFU/100 mL) |
<0.3 | 1* | 17* | <0.3 | <0.3 | <0.3 | <0.3* | <0.3 | <0.3 | <0.3* | <0.3 | 0.3 | 0.3* | <0.3 | <0.3 | |
| Giardia (cysts/100 L) |
1.1 | <0.5* | <0.5* | <0.5 | <0.5 | <0.5 | 2.1* | <0.5 | <0.5 | 2.3* | <0.5 | <0.5 | 1.5* | <0.5 | 1 | |
|
| ||||||||||||||||
| Excess illness (%) | GI | 0.0 | 9.7* | 4.8* | 0.1 | 2.2 | 2.4 | 5.8* | 0.2 | 0.5 | 4.2* | 1.9 | −0.1 | 4.1* | 0.0 | −4.9 |
| Skin | 10.3 | 3.0* | 4.8* | −2.3 | 4.2 | 8.6 | 8.3* | 7.7 | 2.8 | 15.6* | 11.5 | 5.1 | 5.9* | 0.0 | −1.1 | |
| Respiratory | 0.5 | 0.0* | 5.1* | −4.7 | 0.0 | 0.0 | 5.9* | 7.3 | 2.2 | 2.0* | 2.0 | 0.0 | −2.0* | 0.0 | 0.0 | |
| Cumulative | 10.8 | 12.7* | 14.6* | −6.8 | 6.3 | 10.9 | 20.0* | 15.1 | 5.6 | 21.8* | 15.4 | 5.1 | 8.0* | 0.0 | −6.0 | |
*Corresponds to days with highest gastrointestinal illness.